Nobuhiro Kusuba1, Akihiko Kitoh2, Teruki Dainichi1, Tetsuya Honda1, Atsushi Otsuka1, Gyohei Egawa1, Saeko Nakajima1, Yoshiki Miyachi3, Kenji Kabashima4. 1. Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan. 2. Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan. Electronic address: kichu@kuhp.kyoto-u.ac.jp. 3. Shiga Medical Center for Adults, Shiga, Japan. 4. Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan; Singapore Immunology Network and Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), Singapore; PRESTO, Japan Science and Technology Agency, Saitama, Japan. Electronic address: kaba@kuhp.kyoto-u.ac.jp.
Abstract
BACKGROUND: A better understanding of the means by which topical vitamin D analogues exert their therapeutic effect on psoriasis is of theoretical and practical importance. OBJECTIVE: We sought to clarify whether and how the topical vitamin D analogue calcipotriol (CAL) controls the IL-17A-mediated pathogenesis of murine psoriasis-like dermatitis in vivo. METHODS: Psoriasis-like dermatitis was induced by the topical application of an imiquimod (IMQ)-containing cream on the murine ear for 4 to 6 consecutive days. For topical CAL treatment, mice were treated daily with CAL solution on the ear before IMQ application. RESULTS: Mice treated topically with CAL exhibited much milder IMQ-induced psoriasis-like dermatitis compared with vehicle-treated mice, with impaired accumulation of IL-17A-committed T (T17) cells in the lesional skin. The IMQ-induced upregulation of Il12b and Il23a was marked in the epidermis and was abrogated by CAL application, suggesting CAL-mediated suppression of IL-23 expression. CAL inhibited Il12b and Il23a expression by Langerhans cells ex vivo stimulated with IMQ and CD40 cross-linking. Topical CAL also inhibited T17 cell expansion in the draining lymph nodes of IMQ-treated skin, implying a possible effect on T17 cell-mediated dermatitis at distant sites. In fact, topical CAL application on the IMQ-treated left ear resulted in amelioration of T17 cell accumulation and psoriasis-like dermatitis in the right ear subsequently treated with IMQ. CONCLUSION: Topical CAL can exert its antipsoriatic effect on CAL-treated lesions and, concomitantly, distant lesions by attenuating the T17 cell accumulation in both CAL-treated lesions and draining lymph nodes.
BACKGROUND: A better understanding of the means by which topical vitamin D analogues exert their therapeutic effect on psoriasis is of theoretical and practical importance. OBJECTIVE: We sought to clarify whether and how the topical vitamin D analogue calcipotriol (CAL) controls the IL-17A-mediated pathogenesis of murinepsoriasis-like dermatitis in vivo. METHODS:Psoriasis-like dermatitis was induced by the topical application of an imiquimod (IMQ)-containing cream on the murine ear for 4 to 6 consecutive days. For topical CAL treatment, mice were treated daily with CAL solution on the ear before IMQ application. RESULTS:Mice treated topically with CAL exhibited much milder IMQ-induced psoriasis-like dermatitis compared with vehicle-treated mice, with impaired accumulation of IL-17A-committed T (T17) cells in the lesional skin. The IMQ-induced upregulation of Il12b and Il23a was marked in the epidermis and was abrogated by CAL application, suggesting CAL-mediated suppression of IL-23 expression. CAL inhibited Il12b and Il23a expression by Langerhans cells ex vivo stimulated with IMQ and CD40 cross-linking. Topical CAL also inhibited T17 cell expansion in the draining lymph nodes of IMQ-treated skin, implying a possible effect on T17 cell-mediated dermatitis at distant sites. In fact, topical CAL application on the IMQ-treated left ear resulted in amelioration of T17 cell accumulation and psoriasis-like dermatitis in the right ear subsequently treated with IMQ. CONCLUSION: Topical CAL can exert its antipsoriatic effect on CAL-treated lesions and, concomitantly, distant lesions by attenuating the T17 cell accumulation in both CAL-treated lesions and draining lymph nodes.
Authors: Massimo De Martinis; Lia Ginaldi; Maria Maddalena Sirufo; Enrica Maria Bassino; Francesca De Pietro; Giovanni Pioggia; Sebastiano Gangemi Journal: Front Immunol Date: 2021-01-08 Impact factor: 7.561
Authors: Justyna M Wierzbicka; Anna Piotrowska; Dorota Purzycka-Bohdan; Anna Olszewska; Joanna I Nowak; Aneta Szczerkowska-Dobosz; Bogusław Nedoszytko; Roman J Nowicki; Michał A Żmijewski Journal: Int J Mol Sci Date: 2021-11-29 Impact factor: 5.923